Taysha Gene Therapies (TSHA) Assets Average (2020 - 2026)

Taysha Gene Therapies has reported Assets Average for 7 years, with the latest figure at $321.8 million in Q1 2026.

• Quarterly Assets Average rose 115.47% year-over-year to $321.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $321.8 million (up 115.47% YoY) and the FY2025 annual result came in at $251.8 million, up 51.21% from the prior year.
• Assets Average slipped to $321.8 million in Q1 2026 per TSHA's latest filing, from $329.9 million in the prior quarter.
• Over five years, Assets Average peaked at $329.9 million in Q4 2025 and troughed at $91.6 million in Q2 2023.
• A 5-year average of $187.1 million and a median of $170.3 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2026: Assets Average plunged 47.75% in 2022, then surged 115.47% in 2026.
• Over 5 years, Assets Average stood at $118.9 million in 2022, then soared by 55.0% to $184.2 million in 2023, then slipped by 7.58% to $170.3 million in 2024, then jumped by 93.75% to $329.9 million in 2025, then fell by 2.46% to $321.8 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $321.8 million, $329.9 million, and $324.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.